Regenerative therapy with mesenchymal stem cells at the site of malignant primary bone tumour resection: what are the risks of early or late local recurrence?

2014 ◽  
Vol 38 (9) ◽  
pp. 1825-1835 ◽  
Author(s):  
Philippe Hernigou ◽  
Charles Henri Flouzat Lachaniette ◽  
Jerome Delambre ◽  
Nathalie Chevallier ◽  
Helene Rouard
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Local Recurrence ◽  
Bone Tumour ◽  
Tumour Resection ◽  
Regenerative Therapy ◽  
Primary Bone Tumour ◽  
Primary Bone

Long-term outcome of iliosacral resection without reconstruction for primary bone tumours

2020 ◽  
Vol 102-B (6) ◽  
pp. 779-787 ◽  
Author(s):  
Sanjay Gupta ◽  
Anthony M. Griffin ◽  
Kenneth Gundle ◽  
Lisa Kafchinski ◽  
Oren Zarnett ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Functional Outcome ◽  
Bone Tumour ◽  
Oncological Outcome ◽  
Type I ◽  
Segmental Defect ◽  
Primary Bone Tumour ◽  
Primary Bone ◽  
Pelvic Resection

Aims Iliac wing (Type I) and iliosacral (Type I/IV) pelvic resections for a primary bone tumour create a large segmental defect in the pelvic ring. The management of this defect is controversial as the surgeon may choose to reconstruct it or not. When no reconstruction is undertaken, the residual ilium collapses back onto the remaining sacrum forming an iliosacral pseudarthrosis. The aim of this study was to evaluate the long-term oncological outcome, complications, and functional outcome after pelvic resection without reconstruction. Methods Between 1989 and 2015, 32 patients underwent a Type I or Type I/IV pelvic resection without reconstruction for a primary bone tumour. There were 21 men and 11 women with a mean age of 35 years (15 to 85). The most common diagnosis was chondrosarcoma (50%, n = 16). Local recurrence-free, metastasis-free, and overall survival were assessed using the Kaplan-Meier method. Patient function was evaluated using the Musculoskeletal Tumour Society (MSTS) and Toronto Extremity Salvage Score (TESS). Results At a mean follow-up of 159 months (1 to 207), 23 patients were alive without disease, one was alive with lung metastases, one was alive following local recurrence, four were dead of disease, and three had died from other causes. The overall ten-year survival was 77%. There was only one (3%) local recurrence, which occurred at 26 months. There were 18 complications in 17 patients; 13 wound healing complications/infections, three fractures, one pulmonary embolism, and one dislocation of the hip. Most complications occurred early. The mean functional scores were 21.1 (SD 8.1) for MSTS-87, 67.3 (SD 23.9) for MSTS-93 and 76.2 (SD 20.6) for TESS. Conclusion Patients requiring Type I or Type I/IV pelvic resections can expect a good oncological outcome and a high rate of local control. Complications are generally acute in nature and are easily manageable. These patients achieved a good functional outcome without the need for bony reconstruction. Cite this article: Bone Joint J 2020;102-B(6):779–787.

scholarly journals Growth in the Lower Limb Following Chemotherapy for a Malignant Primary Bone Tumour: A Straight-Line Graph

Sarcoma ◽  
1997 ◽  
Vol 1 (2) ◽  
pp. 75-77 ◽  
Author(s):  
Paul Cool ◽  
Mark Davies ◽  
Rob J. Grimer ◽  
Simon R. Carter ◽  
Roger M. Tillman
Keyword(s):  
Lower Limb ◽  
Line Graph ◽  
Bone Tumour ◽  
Straight Line ◽  
Primary Bone Tumour ◽  
Primary Bone

scholarly journals Effects of Hypoxia and Chitosan on Equine Umbilical Cord-Derived Mesenchymal Stem Cells

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
D. J. Griffon ◽  
J. Cho ◽  
J. R. Wagner ◽  
C. Charavaryamath ◽  
J. Wei ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Negative Impact ◽  
Clinical Applications ◽  
Regenerative Therapy ◽  
Defect Model ◽  
Chitosan Films ◽  
Cells Cultured

Chitosan opens new perspectives in regenerative medicine as it enhances the properties of mesenchymal stem cells (MSCs) through formation of spheroids. Hypoxia has also been proposed to enhance stemness and survival of MSCs afterin vivoimplantation. These characteristics are relevant to the development of an off-the-shelf source of allogenic cells for regenerative therapy of tendinopathies. Umbilical cord-derived MSCs (UCM-MSCs) offer an abundant source of immature and immunoprivileged stem cells. In this study, equine UCM-MSCs (eqUCM-MSCs) conditioned for 3 and 7 days on chitosan films at 5% oxygen were compared to eqUCM-MSCs under standard conditions. Equine UCM-MSCs formed spheroids on chitosan but yielded 72% less DNA than standard eqUCM-MSCs. Expression ofSox2,Oct4, andNanogwas 4 to 10 times greater in conditioned cells at day 7. Fluorescence-labeled cells cultured for 7 days under standard conditions or on chitosan films under hypoxia were compared in a bilateral patellar tendon defect model in rats. Fluorescence was present in all treated tendons, but the modulus of elasticity under tension was greater in tendons treated with conditioned cells. Chitosan and hypoxia affected cell yield but improved the stemness of eqUCM-MSCs and their contribution to the healing of tissues. Given the abundance of allogenic cells, these properties are highly relevant to clinical applications and outweigh the negative impact on cell proliferation.

scholarly journals Mechanism of Action of Icariin in Bone Marrow Mesenchymal Stem Cells

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Aofei Yang ◽  
Chaochao Yu ◽  
Qilin Lu ◽  
Hao Li ◽  
Zhanghua Li ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Mechanism Of Action ◽  
Underlying Mechanism ◽  
Bone Defects ◽  
Clinical Use ◽  
Regenerative Therapy ◽  
Herba Epimedii ◽  
Marrow Mesenchymal Stem Cells

Osteoporosis, femoral head necrosis, and congenital bone defects are orthopedic disorders characterized by reduced bone generation and insufficient bone mass. Bone regenerative therapy primarily relies on the bone marrow mesenchymal stem cells (BMSCs) and their ability to differentiate osteogenically. Icariin (ICA) is the active ingredient of Herba epimedii, a common herb used in traditional Chinese medicine (TCM) formulations, and can effectively enhance BMSC proliferation and osteogenesis. However, the underlying mechanism of ICA action in BMSCs is not completely clear. In this review, we provide an overview of the studies on the role and mechanism of action of ICA in BMSCs, to provide greater insights into its potential clinical use in bone regeneration.

scholarly journals Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy

2019 ◽  
Vol 370 (2) ◽  
pp. 231-241 ◽  
Author(s):  
Shen Cheng ◽  
Susheel Kumar Nethi ◽  
Sneha Rathi ◽  
Buddhadev Layek ◽  
Swayam Prabha
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Solid Tumors ◽  
Therapeutic Potential ◽  
Regenerative Therapy

Regional bone change in intramuscular haemangioma mimicking primary bone tumour

2014 ◽  
Vol 59 (2) ◽  
pp. 204-206 ◽  
Author(s):  
Sumer Shikhare ◽  
Julio K Chacko ◽  
Khoon L Chuah
Keyword(s):  
Bone Tumour ◽  
Bone Change ◽  
Primary Bone Tumour ◽  
Primary Bone ◽  
Intramuscular Haemangioma
Sign in / Sign up

Export Citation Format

Share Document